Hainan Huluwa Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of September 2021: 0.95%

Hainan Huluwa Pharmaceutical Group Co Ltd (605199) has an Asset Resilience Ratio of 0.95% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥14.00 Million

≈ $2.05 Million USD Cash + Short-term Investments

Total Assets

CN¥1.48 Billion

≈ $216.34 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Hainan Huluwa Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Hainan Huluwa Pharmaceutical Group Co Lt to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Hainan Huluwa Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 605199 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥14.00 Million	0.95%
Total Liquid Assets	CN¥14.00 Million	0.95%

Asset Resilience Insights

Limited Liquidity: Hainan Huluwa Pharmaceutical Group Co Ltd maintains only 0.95% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Hainan Huluwa Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hainan Huluwa Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Alkem Laboratories Limited NSE:ALKEM	Drug Manufacturers - Specialty & Generic	31.91%
Shan Dong Dong-E E-Jiao Co Ltd SHE:000423	Drug Manufacturers - Specialty & Generic	20.44%
Alkermes plc F:8AK	Drug Manufacturers - Specialty & Generic	3.76%
Jilin Aodong Pharmaceutical Group Co Ltd SHE:000623	Drug Manufacturers - Specialty & Generic	4.97%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Shanghai Haoyuan Chemexpress Co. Ltd. A SHG:688131	Drug Manufacturers - Specialty & Generic	1.37%
Fujian Cosunter Pharmaceutical Co Ltd SHE:300436	Drug Manufacturers - Specialty & Generic	-2.56%

Annual Asset Resilience Ratio for Hainan Huluwa Pharmaceutical Group Co Ltd (None–None)

The table below shows the annual Asset Resilience Ratio data for Hainan Huluwa Pharmaceutical Group Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Hainan Huluwa Pharmaceutical Group Co Ltd

SHG:605199 China Drug Manufacturers - Specialty & Generic

Market Cap

$339.00 Million

CN¥2.32 Billion CNY

Market Cap Rank

#14220 Global

#4228 in China

Share Price

CN¥5.79

Change (1 day)

-0.69%

52-Week Range

CN¥5.19 - CN¥10.20

All Time High

CN¥48.21